Publications by authors named "A A Drosos"
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis.
Expert Opin Biol Ther
August 2024
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that significantly impacts patients' quality of life. While treatment options have expanded over the years, including the introduction of tumor necrosis factor-alpha (TNFα) inhibitors (TNFi), optimizing withdrawal strategies for these agents remains a challenge.
Areas Covered: This review examines the current evidence on TNFi withdrawal strategies in RA, focusing on factors influencing withdrawal decisions such as disease activity monitoring, treatment response, patient characteristics, and biomarkers.
Rheumatoid arthritis (RA) is a chronic inflammatory disease mainly affecting the peripheral diarthrodial joints symmetrically and also presenting many extra-articular manifestations. Morbidity and mortality in RA patients are higher compared to the general population. Cardiovascular (CV) disease is one of the most common causes of death in these patients.
View Article and Find Full Text PDFIntroduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients.
Literature Review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye.
Investigational bispecific antibodies for the treatment of rheumatoid arthritis.
Expert Opin Investig Drugs
July 2024
Article Synopsis
- - Rheumatoid arthritis (RA) is an autoimmune disorder that causes chronic inflammation in the joints and can lead to joint damage if not properly treated, even with existing therapies.
- - Bispecific antibodies (BsAbs) are a new treatment approach that can target two proteins involved in RA, potentially offering improved effectiveness and fewer side effects compared to traditional treatments.
- - Current research shows that BsAbs are promising for RA management, but more studies are needed to refine their use and determine which patients will benefit most from this therapy.